Clinical trials: Vaccination; Infection
Infections, Rotavirus
Safety Study of 2 Formulations of GSK's Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
The purpose of this study is to complete the total safety database size for GlaxoSmithKline Biologicals' (GSK's) human rotavirus (HRV) vaccine across the Porcine circovirus (PCV)-free development plan.
- Trial name
- NCT03954743
- Testing
- PCV-free liquid formulation of GSK's oral live attenuated HRV vaccine, Lyophilized formulation of GSK's oral live attenuated HRV vaccine
- Where
- 37 sites in United States, Canada and 3 more
- Volunteers
- 1,351 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Immune Response Following Seasonal Influenza Vaccination
This is an open-label, single administration dose study in adult healthy male and female subjects. After qualifying for the study, subjects will receive a single intramuscular injection of the FDA approved 2016-2017 quadrivalent…
- Trial name
- NCT03163342
- Testing
- Licensed seasonal influenza vaccine
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Altimmune, Inc.
Dysentery, Bacillary
A Study to Evaluate the Efficacy, Safety and Immunogenicity of a Vaccine Designed to Protect Against Infection With Shigella Sonnei in Healthy Adults
The purpose of this study is to evaluate the efficacy, safety and immunogenicity of the GSK3536852A vaccine, which was designed to protect against shigellosis caused by Shigella sonnei (S.
- Trial name
- NCT03527173
- Testing
- S.sonnei vaccine, S. sonnei 53G challenge strain
- Where
- United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Dengue Fever
Impact of SC vs IM Administration of DENVax (TDV) on Safety and Immunogenicity
This study assessed the safety and immunogenicity of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) previously referred to as DENVax of various dosing schedules via subcutaneous (SC) or intramuscular (IM) administration with…
- Trial name
- NCT01728792
- Testing
- TDV
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Takeda
Influenza
Evaluate Safety & Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults
Since influenza vaccines are administered every year because of the frequent change in their antigenic composition, the safety and immunogenicity profile of GSK Biologicals' influenza vaccine GSK576389A will be re-evaluated after…
- Trial name
- NCT00529516
- Testing
- Fluarix, GSK Biologicals Influenza Vaccine GSK576389A
- Where
- 29 sites in United States, Belgium and 2 more
- Volunteers
- 1,252 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19
Safety and Immunogenicity Study of Booster Vaccination With COVID-19 Vaccine (Vero Cell),Inactivated From Different Manufactures for Prevention of COVID-19
This is a randomized, Open, control phase Ⅳ clinical trial of inactivated COVID-19 vaccine manufactured by Sinovac Research \& Development Co., Ltd,Beijing institute of Biological Products Co.,Ltd and Wuhan Institute of…
- Trial name
- NCT05165732
- Testing
- Experimental vaccine 1, Experimental vaccine 2, Experimental vaccine 3
- Where
- China
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
Tuberculosis
Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in BCG Vaccinated Volunteers
This is a two-part randomized, placebo-controlled, observer-blind, safety and dose-finding Phase Ib/IIa study. This study will evaluate up to four dose levels of the BNT164 investigational vaccines (BNT164a1 and BNT164b1) to…
- Trial name
- NCT05547464
- Testing
- BNT164a1, BNT164b1
- Where
- 8 sites in Mozambique, South Africa
- Volunteers
- 497 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Influenza Immunization
Repeated Cross Sectional Surveillance Study To Determine the Influenza Vaccination Rates in German Participants
Real-time monitoring of vaccination rates for Germany is unavailable, and up-to-date data publication is delayed, which makes it challenging to develop effective public health strategies to increase vaccination coverage.
- Trial name
- Vakzimeter FLU (NCT06800885)
- Where
- Germany
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza Immunization
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older
The purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular (IM) injection of up to 3 dose levels of Quadrivalent Influenza mRNA Vaccine MRT5410 compared to an active control (QIV SD, QIV HD…
- Trial name
- NCT05624606
- Testing
- Quadrivalent Influenza mRNA Vaccine MRT5410, Quadrivalent Recombinant Influenza vaccine RIV4, Quadrivalent Inactivated Influenza Standard Dose QIV-SD
- Where
- 25 sites in United States, Puerto Rico
- Volunteers
- 682 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Diphtheria, Tetanus
Antibody Persistence in Healthy Children After Primary and Booster DTaP-IPV-Hep B-PRP-T Vaccine or Control Vaccine
The purpose of this study is to evaluate the long term immunogenicity produced in children by the investigational hexavalent vaccine (DTaP-IPV-Hep B-PRP-T) given in Study A3L15 (NCT 00362336).
- Conditions
- Diphtheria, Tetanus, Whooping Cough, Hepatitis B
- Trial name
- NCT01105559
- Where
- 2 sites in South Africa
- Volunteers
- 455 people, healthy volunteers welcome
- Sponsor
- Sanofi
Malaria, Plasmodium Falciparum
Controlled Human Malaria Infection (CHMI) After Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis
The purpose of the study is to determine the safety and tolerability of ID administration of PfSPZ Challenge to volunteers taking chloroquine chemoprophylaxis (an approach called PfSPZ-CVac).
- Trial name
- NCT01728701
- Testing
- PfSPZ Challenge, Normal Saline (NS)
- Where
- Netherlands
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Influenza
Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine
This study is to evaluate the safety, tolerability and immune response when 13-valent pneumococcal conjugate vaccine (13vPnC) and the trivalent inactivated flu vaccine (TIV) are given together to healthy adults aged 50-59 years…
- Trial name
- NCT00521586
- Testing
- 13 valent pneumococcal conjugate vaccine
- Where
- 41 sites in United States
- Volunteers
- 1,116 people, healthy volunteers welcome
- Sponsor
- Pfizer
Japanese Encephalitis
Safety Surveillance After Immunization With IXIARO
This is an active electronic surveillance using data from the Defense Medical Surveillance System (DMSS) to detect and characterize serious, rare adverse events occurring within 42 days after vaccination with the Japanese…
- Trial name
- NCT01335412
- Testing
- Japanese Encephalitis Virus vaccine, inactivated, adsorbed
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- Valneva Austria GmbH
HPV Infections, Cervical Cancer Stage IIa
Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine
To access the immune persistence of Chinese women aged 9-45 years after receiving quadrivalent HPV vaccine with the immunization schedule of 0, 2 and 6 months.
- Conditions
- HPV Infections, Cervical Cancer Stage IIa, Vaginal Cancer, Genital Wart
- Trial name
- NCT05371353
- Where
- 2 sites in China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Tuberculosis, Multidrug Resistant
Safety of RUTI® Vaccination in MDR-TB Patients
Prospective, randomized, double-blind, multicentre, placebo-controlled clinical phase IIa trial to evaluate safety and immunogenicity of RUTI® vaccine in Multidrug-resistant Tuberculosis (MDR-TB) patients favourably responding to…
- Trial name
- NCT02711735
- Testing
- RUTI® Therapeutic vaccine
- Where
- 3 sites in Ukraine
- Volunteers
- 9 people
- Sponsor
- Archivel Farma S.L.
Influenza
Evaluation of the Protective Efficacy and Safety of CR8020 in an Influenza Challenge
After prophylactic vaccination with CR8020, a monoclonal antibody, subjects will be challenged with the H3N2 virus. The protective efficacy, safety, tolerability, pharmacokinetics, and potential immunogenicity will be assessed.
- Trial name
- NCT01938352
- Testing
- CR8020
- Where
- United Kingdom
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Prevention of Meningococcal Infection
Persistence of Immune Response After Vaccination With MCC
Persistence of Immune response after vaccination with MCC
- Trial name
- NCT00310687
- Testing
- BLOOD DRAW
- Where
- United Kingdom
- Volunteers
- 1,244 people, healthy volunteers welcome
- Sponsor
- Novartis
Hib Disease, Hepatitis B
Immune Memory Foll Pry Vaccination With DTPw-HBV/Hib Vaccine Formulation; Immuno & Reacto of Booster Dose at 15-18 Mths
To assess the anti-PRP antibody response one month after vaccination in the groups receiving a fourth consecutive dose of two formulations of DTPw-HBV/Hib vaccine
- Conditions
- Hib Disease, Hepatitis B, Pertussis, Prophylaxis of Diphtheria
- Trial name
- NCT00158808
- Testing
- Diphteria, tetanus, whole-cell pertussis, hepatitis B & Hib
- Where
- Philippines
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19 Vaccination
Korean Post Marketing Surveillance for Comirnaty Injection (Bretovameran)
This study is to identify any problems and questions with respect to the safety of Comirnaty Injection (Bretovameran) during the post-marketing period.
- Trial name
- NCT06613984
- Testing
- Bretovameran
- Where
- South Korea
- Volunteers
- 660 people, healthy volunteers welcome
- Sponsor
- Pfizer
Poliomyelitis
A Post-marketing Safety Study of GSK Bio IPV Vaccine (PoliorixTM) in Korean Children
Following licensing of PoliorixTM in Korea, this study will collect safety data about the routine use of this vaccine in 600 children according to the regulations of Korean Food and Drugs Administration (KFDA).
- Trial name
- NCT00514033
- Testing
- Poliomyelitis vaccine (inactivated) -PoliorixTM
- Where
- South Korea
- Volunteers
- 349 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline